Table 4 Symptom outcomes by bamlanivimab dose cohort and treatment arm

Time to symptom improvement from study entry (primary symptom outcome), median (IQR), days

21.0 (7.0, 28.0)

18.5 (7.0, 28.0)

0.97^a

24.0 (14.0, 28.0)

20.5 (9.0, 28.0)

0.08^a

Proportion of participants with at least 1 symptom reported as more severe than at study entry in study diary, n (%)

42 (87.5)

40 (87.0)

0.94^b

102 (91.9)

105 (93.8)

0.59^b

Symptom severity ranking (AUC of total symptom score days 0–28), median (IQR)

1.38 (0.93, 3.09)

1.88 (1.09, 3.05)

0.14^a

2.34 (1.30, 3.93)

2.13 (1.06, 4.08)

0.65^a